Some authors have indicated that the downregulation, loss of expression, and deletion of PCDH9 were associated with the progression of prostate cancer [29], epithelial ovarian cancer [30], glioma [31,32], and gastric cancer [33]. Here, PCDH9 is linked to prostate carcinoma.